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Abstract
Introduction
On the basis of results from the National Lung Screening Trial
(NLST),  national  guidelines  now recommend using  low-dose
computed tomography (LDCT) to screen high-risk smokers for
lung cancer.  Our study objective was to characterize the know-
ledge, attitudes, and beliefs of primary care providers about imple-
menting LDCT screening.
Methods
We conducted semistructured interviews with primary care pro-
viders practicing in New Mexico clinics for underserved minority
populations. The interviews, conducted from February through
September 2014, focused on providers’ tobacco cessation efforts,
lung cancer screening practices, perceptions of NLST and screen-
ing guidelines, and attitudes about informed decision making for
cancer screening. Investigators iteratively reviewed transcripts to
create a coding structure.
Results
We reached thematic saturation after interviewing 10 providers
practicing in 6 urban and 4 rural settings; 8 practiced at federally
qualified health centers. All 10 providers promoted smoking ces-
sation, some screened with chest x-rays, and none screened with
LDCT. Not all were aware of NLST results or current guideline
recommendations. Providers viewed study results skeptically, par-
ticularly the 95% false-positive rate, the need to screen 320 pa-
tients to prevent 1 lung cancer death, and the small proportion of
minority  participants.  Providers  were  uncertain  whether  New
Mexico had the necessary infrastructure to support high-quality
screening, and worried about access barriers and financial bur-
dens for rural, underinsured populations. Providers noted the com-
plexity of discussing benefits and harms of screening and surveil-
lance with their patient population.
Conclusion
Providers have several concerns about the feasibility and appropri-
ateness of implementing LDCT screening. Effective lung cancer
screening programs will need to educate providers and patients to
support informed decision making and to ensure that high-quality
screening can be efficiently delivered in community practice.
Introduction
The National Lung Screening Trial (NLST) showed that lung can-
cer screening with low-dose computed tomography (LDCT) signi-
ficantly reduced lung cancer deaths among heavy smokers com-
pared with screening with chest x-ray (1). The US Preventive Ser-
vices Task Force (USPSTF) subsequently issued a B recommend-
ation supporting LDCT screening (2). The recommendation is im-
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portant because the Affordable Care Act mandates first-dollar cov-
erage for preventive services graded A or B by the USPSTF (3). In
February 2015, the Centers for Medicare and Medicaid Services
(CMS) proposed that evidence is sufficient to provide annual LD-
CT screening for patients and in centers meeting eligibility criter-
ia (4). The American Lung Association (5) and American Cancer
Society (6) also support LDCT screening. However, the American
Academy of Family Physicians determined that the evidence was
insufficient to recommend for or against lung cancer screening
with LDCT (7).
Translating results of an efficacy trial conducted largely in aca-
demic medical centers into routine community practice may be
challenging. Nearly all participants in the NLST were white, their
socioeconomic status was higher than the general population, and
they were adherent to recommended testing (1). US population
data show marked racial/ethnic and socioeconomic disparities in
lung cancer mortality, prevalence of smoking, stage at diagnosis,
and adherence to cancer screening (8,9). New Mexico, the setting
for our study, is a large, sparsely populated minority–majority
state (non-Hispanic whites make up less than 50% of the popula-
tion) characterized by low socioeconomic status and limited health
care resources (10).
Documenting the perspectives of providers caring for racially/eth-
nically and socioeconomically diverse populations is necessary for
planning screening implementation. However, few studies have
evaluated physician attitudes and practices regarding LDCT lung
cancer screening (11–14), and US studies were conducted before
NLST results and screening recommendations were published.
Therefore, we interviewed primary care clinicians practicing in
New Mexico to characterize their knowledge, attitudes, and be-
liefs about LDCT lung cancer screening.
Methods
Study setting and sample
We conducted qualitative in-depth, semistructured interviews with
primary care provider members of the Research Involving Outpa-
tient Settings Network (RIOS Net), the practice-based research
network of New Mexico (15). Approximately one-third of RIOS
Net members practice in federally qualified community health care
centers that predominantly serve Hispanic patients. By using a
purposeful sampling approach, we identified rural and urban clini-
cians whose patients met criteria for LDCT screening. The Uni-
versity  of  New Mexico  Health  Sciences  Center’s  Human Re-
search Protections Office approved the study. We obtained con-
sent by reviewing the consent form with each provider prior to the
interview.
Data collection
We developed an interview guide (Appendix) that focused on the
domains of knowledge,  attitudes,  and beliefs  regarding LDCT
lung cancer screening that we believed to be relevant to the poten-
tial uptake and implementation of new primary care services, per-
ceived patient receptivity to screening, perceived decisional influ-
ences, barriers and facilitators, perceived patient receptivity to
smoking cessation and relapse prevention, perceived decisional in-
fluences, and views about cultural factors related to screening and
smoking behaviors among Hispanic and other racial/ethnic minor-
ity and underserved populations. Additionally, we asked about the
feasibility  of  effectively  engaging  patients  in  screening  and
smoking cessation discussions.
We conducted the interviews from February through September
2014. We mailed the materials about the study and lung cancer
screening to primary care providers up to 1 week before the inter-
view. Materials included the informed consent form, a summary of
the NLST study design and results,  a summary of lung cancer
screening guidelines developed by national organizations (Americ-
an  Cancer  Society,  USPSTF,  and  the  American  Lung
Association),  and  a  pictogram that  graphically  displayed out-
comes (true–false positives rates, absolute mortality benefits) of
lung cancer screening based on the NLST. Providers could refer to
these materials during the interview. The digitally audio-recorded
interview lasted about 60 minutes and was transcribed. All but 1
interview was conducted in person; providers received a $50 mer-
chandise card for participating.
Data analysis
We used a content-driven immersion and crystallization approach
to data analysis, which consisted of a systematic iterative process
of transcript content review to identify themes of importance (16).
Each research team member independently read sets of 2 or 3 tran-
scripts to identify preliminary findings. This process enabled us to
modify the interview guide to confirm emerging themes, discon-
firm anomalous results, and pursue unanticipated issues. Through
the use of these verification strategies, the lead qualitative ana-
lysts (A.M., C.G., A.S.) created an initial coding structure that was
continually  revised  during  the  data  collection  until  the  team
reached consensus (17).  We then imported the transcripts into
NVivo 10 (QSR International), a qualitative data analysis soft-
ware program, for coding. We grouped data into broad categories
to guide theme development. After coding all transcripts, we quer-
ied the database by coding categories for a more refined level of
interpretive analysis. The team iteratively reviewed these reports
to  identify  and crystallize  major  analytic  themes.  We reached
thematic saturation after interviewing 10 primary care providers.
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Results
The 10 primary care providers included 2 physician assistants; all
were family medicine clinicians. Eight practiced at federally quali-
fied health centers and 4 in rural settings; 4 were women.
Current practices for smoking cessation and lung cancer screening.
Providers reported usually inquiring about tobacco use and estim-
ated that about 10% to 40% of their patients would meet LDCT
screening eligibility criteria, with highest rates among men (Table,
quote 1). However, providers noted that male smokers were least
likely to come in for preventive health care, because they usually
accessed the health care system only when they were sick. Pro-
viders reported counseling smokers about cessation, identifying
resources such as quit lines, and prescribing nicotine replacement
therapy, bupropion, or varenicline. Some ordered a baseline chest
x-ray for smokers, particularly for those with lung disease, expect-
ing that abnormal results could serve as a scare tactic. One pro-
vider  believed that  ordering a chest  x-ray alone might  prompt
some smokers to consider quitting.
No clinician ordered LDCT scans for lung cancer screening, and
none reported any patient demand for such screening. Some were
unaware of LDCT screening, whereas others reported LDCT was
just “getting on their radar” (Table, quote 2). Among providers
who order chest x-rays, some explained that they believed they
were  following national  guidelines  and others  were  uncertain
whether screening with LDCT was superior to using chest x-ray.
Interpreting NLST evidence. Not all providers were aware of the
LDCT results. When we presented summaries of the trial a few
were positive about screening, but most viewed the data with some
skepticism. They perceived the absolute mortality risk benefit to
be small; the number of patients who would need to be screened in
order to prevent 1 lung cancer death was seen as high. Other pro-
viders wanted to see evidence that screening was efficacious for
different  populations  and  indicated  hesitance  about  initiating
screening based solely on 1 trial. There was considerable concern
about the potential harm of screening. Providers often cited the
high  rate  of  false-positive  results  and  their  downstream con-
sequences. Subsequent diagnostic testing, particularly invasive
procedures, further affect patients by complicating risks from dia-
gnostic procedures, missing work, arranging transportation to an
imaging center, and facing insurance copayments. Some wanted to
see a lower false-positive rate before widely adopting LDCT. Con-
cerns about the health risks from long-term radiation exposure
would deter some from ordering LDCT screening (Table, quotes
3–5).
Perspectives on screening guidelines. Not all providers were aware
of the recent changes to national cancer screening guidelines to in-
clude LDCT; a few believed that guidelines recommended screen-
ing with a chest x-ray. Although some were inclined to follow
screening recommendations (“even if one life is saved, it is a good
procedure”), others felt that the guidelines were still too nebulous.
The USPSTF B rating was problematic for some providers, who
tended to aggressively counsel patients only for A-rated prevent-
ive services. They expected a convincing standard of evidence to
support guidelines leading to rapid changes in practice, which they
felt was not met for lung cancer screening (Table, quotes 6–7).
Providers welcomed the clear selection criteria related to age and
smoking history but were concerned about continuing screening
until age 80, an upper age limit that went beyond the NLST inclu-
sion criteria. They also believed that the guidelines did not suffi-
ciently address the appropriateness and safety of screening pa-
tients with multiple chronic conditions. Additionally, they noted
that USPSTF recommendations did not factor in potential out-
comes following a negative screening result,  including a false
sense of reassurance and continued use of tobacco products (Ta-
ble, quote 8).
Providers discussed their experiences with the evolving changes to
mammography and prostate specific antigen screening guidelines,
which led to increased scrutiny about the value of all screening
tests. Some believed that lung cancer screening needs to be viewed
in the broader context of the overall risks, benefits, and costs for
all screening programs. They also pointed out that survival bene-
fits  might be more attributable to improved treatments than to
screening efforts (Table, quotes 9–10).
Implementing screening. Most providers were cautious and ambi-
valent about offering lung cancer screening, preferring to take a
“wait and see” approach (Table, quotes 11–12). However, given
the  USPSTF  recommendation,  many  expected  that  screening
would eventually be implemented at their practice sites. Providers
felt that they will be obligated to offer screening if it becomes a
performance measure. Furthermore, some were concerned about
the potential legal implications associated with not having offered
either chest x-ray or LDCT to a patient who subsequently devel-
ops lung cancer.
Providers  identified  many  potential  barriers  to  implementing
screening. One concern related to following up on abnormal test
results given the range of possible diagnostic and surveillance test-
ing options. Radiologists would need to provide primary care pro-
viders clear guidance about addressing positive findings, but pro-
viders were also worried about whether New Mexico had the in-
frastructure  to  support  the high-quality  screening program re-
quired by guidelines. Screening rural patients annually would be
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particularly problematic given the lack of local technology and
resulting travel burdens. Most were concerned about the costs for
follow-up testing after positive screening results and the costs of
treating cancer, which could be prohibitive for many patients (Ta-
ble, quote 13). Additionally, they recognized that patients, particu-
larly in rural areas, would incur substantial costs related to travel
and lost income from taking time off from work. Although many
potentially eligible clinic patients were using Medicaid or Medi-
care, others were self-paying, either uninsured or uninsurable (un-
documented immigrants). Providers indicated that their screening
decisions would be heavily influenced by socioeconomic status.
Integrating an additional screening program was perceived as po-
tentially overloading an already stressed primary care system (Ta-
ble, quote 14). Providers described facing many competing pa-
tient demands and already lacking time to engage in counseling
about valuable preventive care services. One physician noted that
effectively addressing LDCT screening in primary care would re-
quire a system redesign (Table, quote 15). However, providers
also recognized that clinics, especially federally qualified health
centers, were already overwhelmed with the new requirements of
the Affordable Care Act and meaningful use of electronic health
records (Table, quote 16). Many providers indicated that incorpor-
ating any new preventive service would be a slow process.
Screening counseling.  Providers wrestled with counseling about
screening because they considered screening to be a complex is-
sue, particularly regarding abnormal results that did not clearly
suggest cancer. Presenting the idea that an abnormal test result is
not definitive (“we don’t know what it means”) and that further
testing is required could be challenging given the low literacy of
many of the patients and the limited available discussion time dur-
ing clinic visits. One respondent noted that patients do not under-
stand risk, particularly the concept of absolute versus relative risk,
so would have difficulty making informed decisions about lung
cancer screening. Providers did mention the importance of provid-
ing concrete information so that patients could relate to estimates
for risk and benefit. However, providers were also worried about
the challenges of helping patients understand the potential down-
stream consequences  of  screening  without  scaring  them.  Pro-
viders were themselves uncertain about the follow-up of abnormal
test results and were uncomfortable advising patients about lung
cancer screening. Some indicated that the challenges in describing
the risks and benefits might actually prevent them from discuss-
ing screening. Finally, providers recognized that current screening
guidelines could commit eligible patients to decades of screening.
However, they would support patients who wanted to opt out and
understood, based on their experiences with breast and prostate
cancer  screening,  that  guidelines  could change (Table,  quotes
17–19).
Ethical considerations. Lastly, providers raised several potential
ethical issues. One provider sensed that offering screening in un-
derserved communities represented a form of health equity be-
cause rural patients are often excluded from latest advances (Ta-
ble, quote 20). However, others considered it ethically wrong to
offer screening to patients who cannot afford follow-up care. An-
other provider, who was unwilling to offer screening, was con-
cerned  about  the  societal  costs  of  “free”  screening,  because
nonsmokers are paying premiums for smokers to receive screen-
ing (Table, quote 21). A few providers questioned the value of de-
voting limited health care resources to LDCT screening among
older, hard-core smokers. They instead advocated for focusing
cancer control efforts on the young to achieve greater societal be-
nefit by creating environmental barriers and financial disincent-
ives to starting or continuing smoking.
Discussion
This qualitative study of primary care providers practicing in New
Mexico raised important concerns about implementing lung can-
cer screening. Providers felt that the state might have limited capa-
city to provide the high-volume, high-quality lung cancer screen-
ing and treatment centers required to support screening programs.
Access and cost would likely be important patient barriers to im-
plementing screening, and respondents also were concerned about
the feasibility of integrating yet another screening recommenda-
tion into routine practice. Several providers were not fully aware
of  the  NLST  results  or  of  the  major  lung  cancer  screening
guidelines, and they indicated that they would need guidance in
advising patients about the screening process. They also identified
ethical issues related to resource allocation.
Providers were skeptical about incorporating another preventive
service into their practice, not only because of time constraints but
also because of the complexity of explaining and coordinating
screening and follow-up. Although USPSTF recommendations
carried weight, respondents indicated that a performance measure
would make screening a higher priority. CMS support for LDCT
will likely have a major impact on whether health care systems
and organizations, such as the National Center for Quality Assur-
ance, focus on screening by developing a measure for the Health
Care Effectiveness Data and Information Set (HEDIS).
A consistent message in the guidelines is that providers should
help patients make informed screening decisions. However, not all
our  respondents  were  aware  of  the  evidence  on  lung  cancer
screening or of national guideline recommendations. These find-
ings  are  similar  to  a  national  survey conducted in  2006–2007
showing  practice  patterns  at  variance  with  evidence  and
guidelines. For example, some providers ordered sputum cytology
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or screened never smokers,  although at  that  time of the study,
guidelines did not recommend lung cancer screening (11,12). Edu-
cating primary care providers about evidence and recommenda-
tions will be a necessary step in implementing lung cancer screen-
ing. Although some providers suggested continuing medical edu-
cation training, an approach that has shown some effectiveness for
changing practice (18), a more practical approach might be to de-
velop provider decision support tools that summarize the clinical
evidence and guideline recommendations for lung cancer screen-
ing and provide guidance on offering smoking cessation counsel-
ing and referrals. The USPSTF developed a 1-page information
sheet on lung cancer screening for providers (19). Given the com-
plexity of screening issues, the American Cancer Society called
for primary care providers to develop competency in shared de-
cision making, which they describe as a rapidly emerging obliga-
tion for primary care (6). Implementing shared decision making
may also allay provider concerns (20) about malpractice and un-
warranted patient requests (12,13). The American Lung Associ-
ation is developing a toolkit to assist at-risk patients in discus-
sions with physicians (though not specifically with primary care
providers) (5), and a patient decision aid is being evaluated in a
Patient-Centered  Outcomes  Research  Institute  grant  (21).
However, multidisciplinary teams comprising radiologists, pul-
monologists, and oncologists with expertise in evaluating, dia-
gnosing, and treating abnormal lung findings will likely need to
assume responsibility for supporting decision making once an ab-
normality is detected through LDCT screening, including decision
making about invasive diagnostic procedures and surveillance test-
ing.
Our respondents brought up important concerns about the costs of
screening for  individual  patients.  Although the costs  of  initial
screening tests are covered under the Affordable Care Act, health
care systems and health departments will still need to address the
uncertain coverage of surveillance imaging, invasive diagnostic
procedures, and cancer treatment that could burden the patient.
Respondents  were  also  concerned  about  the  overall  costs  of
screening programs and questioned whether New Mexico has the
necessary resources to implement lung cancer screening. The soci-
etal costs of a lung cancer screening program could be prohibitive
given the estimated 8.7 million US adults eligible for screening
(22). An economic analysis suggested that the national costs of
implementing LDCT screening would be $1.3 to $2.0 billion dol-
lars annually; while screening (with 75% uptake) could avoid up
to 8,100 premature lung deaths cancers,  the additional  cost  of
screening to avoid 1 death would be about $240,000 (23). Based
on  NLST findings,  the  estimated  cost-effectiveness  of  LDCT
screening would be $81,000 per quality-adjusted life year (24).
However, the estimate was sensitive to model assumptions; costs
could be higher depending on how screening is implemented in
community settings.
The majority of our respondents believed that interventions to con-
trol lung cancer should be linked to interventions to control to-
bacco use (14). A cost–utility analysis indicated offering smoking
cessation interventions with annual screening would increase the
cost-effectiveness of lung cancer screening by 20% to 45% (25).
Interestingly, some respondents raised ethical concerns about al-
locating resources to screening for lung cancer rather than to con-
trolling tobacco use, their reasoning being that helping smokers,
particularly younger smokers,  to quit  would be a more ethical
method of controlling the incidence of lung cancer than screening
smokers to learn whether they already have lung cancer.
Our study has some limitations. The sample size was small, al-
though we quickly reached saturation in our themes. We inter-
viewed providers caring for underserved minority patients, and the
attitudes and beliefs of providers in our study might differ from
those of providers practicing in different settings. However, given
that most US primary care providers are not practicing in settings
comparable  with  the  academic centers  that  participated in  the
NLST, our findings are likely to be broadly generalizable. In addi-
tion, we distributed materials about LDCT screening to providers
before the interviews, which may have influenced their responses.
However, none of our respondents were screening with LDCT,
and we found it  necessary to provide this  material  to  produce
meaningful discussions. Because we provided information only
about lung cancer screening, respondents could not readily com-
pare study findings and guidelines with other screening programs.
Nonetheless, we presented material adapted from guidelines is-
sued by prominent organizations, such as the USPSTF, American
Cancer Society,  and American Lung Association,  which clini-
cians routinely review to guide screening practices. Furthermore,
clinicians indicated awareness of the controversies surrounding
prostate and breast cancer screening programs.
Our findings have some important implications for lung cancer
screening  in  New  Mexico.  The  American  Cancer  Society
guideline explicitly advised offering screening only if eligible pa-
tients could access an appropriate screening and treatment center
(6). If New Mexico has the necessary infrastructure to implement
screening, it will likely be in a limited number of urban settings,
which would create access problems for rural patients. Screening
may also be fragmented, with opportunistic screening occurring in
settings without ready access to diagnostic procedures and treat-
ment. As encouraged by the USPSTF (2) and required by CMS
(4),  New Mexico  should  consider  creating  a  registry  to  track
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screening practices and outcomes, including abnormal LDCT find-
ings, invasive diagnostic testing and complications, and treatment
outcomes. Resource use and cost data should also be collected to
determine the most cost-effective strategies. Such a registry would
help determine how well NLST results translate into practice and
identify quality improvement efforts to address gaps.
Given limited resources, screening programs will need further effi-
ciencies, including identifying high-risk patients who would most
benefit from screening. A post-hoc analysis of NLST data sug-
gests that targeting screening to the 3 highest risk quintiles (based
on age, body mass index, family history of lung cancer, smoking
history,  and emphysema diagnosis)  would account for 88% of
screening-prevented lung cancer deaths (26).  Conversely, pro-
viders will need to avoid screening patients who do not meet cri-
teria or who are too sick to benefit. Previous surveys suggest that
some primary care providers would not routinely consider a pa-
tient’s age, tobacco use, or exposure to tobacco smoke when de-
ciding whether to recommend screening (11,12,14).
We conducted what we believe is the first US qualitative provider
study following publication of NLST results and issuance of the
USPSTF lung cancer screening guidelines.  Implementing lung
cancer screening will be challenging, particularly in underserved
areas. The program will require ensuring access to the necessary
infrastructure, closely adhering to screening guidelines, address-
ing costs for both patients and health care systems, and supporting
shared decision making. Even if screening programs are not estab-
lished, providers will need help counseling patients who request
screening or who have undergone opportunistic testing. Policy
makers  will  need  to  consider  establishing  registries  to  track
screening practices and outcomes and will also need to determine
whether allocating resources to screening is the most cost-effect-
ive approach to controlling the burden of lung cancer.
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Table
Table. Primary Care Provider Comments About Lung Cancer Screening, New Mexico, February to September, 2014
Domain Provider Comments
Current practices for smoking
cessation and lung cancer
screening
1. “Yes. I think a lot of people do [fall into screening eligibility category]. Um . . . in that age group I
would say it’s probably a good . . . upwards of 25%.”
2. “Yeah, I actually had no idea. I read this guideline stuff right before . . .  like earlier this morning and
I was like, ‘I had no idea the USPSTF even like recommended this.’ I knew nothing about it. In fact,
when you sent the email about the study, I was like, ‘we’re supposed to be screening for lung cancer?’
I had no idea at all.”
Interpreting evidence from the
National Lung Screening Trial
3. “I mean, you are putting someone at harm I guess, I mean, that’s a lot of radiation exposure.
There’s not a huge difference between the group that was screened and not screened. Three people
is not a huge difference, and the fact that 365 people had a false positive. It’s like way more people
had a false positive than like a real positive and for a screening test it doesn’t seem like a great test.”
4. “I think I feel very ambivalent about somebody doing one of these studies. I think the biggest thing
for me is that we’ve got . . .  it’s like we have 3 fewer deaths. Right? Out of per thousand. But then per
those thousand people, 3 people are having major complications.”
5. “And then just physical access to getting the test. I mean, here’s a patient of mine who I say, ‘hey,
you’re gonna need to go here, wherever, to get this,’ [and the patient says] ‘okay, let’s see, buy my
medicine for two weeks, or pay for gas to go do this. Let’s see, okay should I get that ultrasound, well I
guess we can go on tortillas and beans for the week, for me and the two kids, or I can do that to try
and make it work to get the money to do this particular exam.’”
Perspectives on screening
guidelines
6. “I see what the grade recommendation is. Is it a ‘C’? It’s not that great. Then I won’t do it for
everybody, like if it was an ‘A’ then I should be doing that. That’s how that integrates into my practice.”
7. “It comes up a lot with a lot of our screening tests that are recommended. Like they’re level B
evidence or something and you could do it but it’s just like it’s Pandora’s Box so you do it and it’s not a
great screening test, um, where like the number needed to screen is like also in the hundreds and
then it . . . there’s all these false positives and procedures.”
8. “It’s something I worry about . . . is this person feeling like, ‘Oh well, I’ve got a clean bill of health.
My lungs are fine. I might as well puff away.”
9. “Well, I think the harm of testing, you know, the false-positive rate and what that actually means is
the number-one concern with any test we do. I think we’ve just gone through this or are still going
through this with PSA [prostate specific antigen] and prostate cancer screening, and we’re still trying
to figure out how to have that conversation.”
10. “I feel like the more I learn about screening, the more I’m reticent and kind of, you know,
everything coming out around mammography and obviously we no longer recommend PSAs and
prostate cancer screening. I feel like I needed some time to absorb it and find the time to read
everything and try to figure out what’s going on, but it’s definitely been on my radar.”
Implementing screening
11. “[W]ithout having further information about this, and with the limited reading I’ve done on this, I
probably um . . .  it’s not . . .  because it’s not a guideline that’s in stone yet, I probably would not be
inclined to offer it to every single person who is in this category.”
12. “Definitely my initial thought looking through the data was like, ‘I’m not gonna do this . . . yeah,
seems like way too much . . . the radiation exposure is a lot per year and the cost of this kind of
screening is humongous. It’s not like we’re doing x-rays on everybody, we’re doing CTs.”
13. “We shouldn’t be screening people if we know that they can’t afford it or if it’s going to represent a
massive financial burden and then follow-up. I hadn’t even thought about the fact that maybe they
won’t be covering the work-up afterwards, which is probably true because the work-up is going to be
pretty expensive. That really worries me.”
14. “It’s a matter of where you put your resources. We could all come up with our priority list, much of
which would be probably above this [screening]. Basic medications, other tests that patients are
having, physical therapy patients are having to pay 40% of the co-pay. It would just seem from a policy
perspective that those kind of more low-tech approaches may be a better way to use resources, in the
big picture.”
(continued on next page)
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(continued)
Table. Primary Care Provider Comments About Lung Cancer Screening, New Mexico, February to September, 2014
Domain Provider Comments
15. “We really need to come up with probably a totally different model for prevention and screening
activities that is parallel to primary care in terms of acute and chronic care, which is not to say that the
primary care clinician cannot or should not be doing the best they can with their limited time with the
patient, but in addition to that there should be some very different model for prevention and screening
activity. As you know in many countries around the world that there’s just a whole separate system for
prevention and screening, which again, can be paired with primary care, acute and chronic care, but
to, to keep thinking that we can just keep adding to a list of things that, you know, the primary care
provider’s supposed to do in their 20-minute visit is, is just silly and naïve and spinning our wheels
and actually creating various problems.”
16. “System changes have left providers in a worse position to address important things like
prevention screening, education, medication management, self-management . . . all these things
which are pretty critical to really improving the health of patients.”
Screening counseling
17. “A lot of it depends on how we’re able to boil it down for them . . . help them understand and
make their decision. We influence that whether we want to or not. We influence their decision based
on how we present it. It could be a slippery slope. I find that folks are like, ‘I don’t want to know and
then be worrying about something or freaked out.’ Having this kind of discussion takes a high level of
health literacy. It's hard to explain these kind of numbers.”
18. “I think that is the most basic level of understanding, ‘hey, there’s a test and doctors can do this
test and it’s like, yes or no, you have something or you don’t.’ And then the next level of understanding
is what does that something mean? That means I could have a nodule and from there on I would say
the majority of my patients would have no concept. It’s like they tune out or it’s just too difficult for
them to wrap their head around that.”
19. “I think if there were a way to play a video in the room because we are gonna have computers in
the room. If we get to that level of technical ability then that’d be nice. Some of my patients can’t read
so that would be another benefit.”
Ethical considerations
20. “People are actually desperate to receive quality care. It’s actually depressing that most of our
patients have heard about good and helpful and important health care that apparently some people
receive out in the world but that they don’t get to receive because of access problems. So folks are
desperate and anxious for the day to come when they’ll have access to the kinds of things they see on
TV.”
21. “Yeah, and even if it’s not necessarily like a cost to the patient, it would be, you know, someone’s
paying for it . . . other people who haven’t smoked are paying the premiums for people who like have
smoked and are now getting these CTs every year.”
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Appendix. Primary Care Provider Interview Guide
This file is available for download as a Microsoft Word document [DOCX — 26 KB].
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